# Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Source: https://onco.cc/trials/nct05511844/  
OnCo record `nct05511844` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ORM-5029 run by Orum Therapeutics USA, Inc., terminated.

## Summary

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors is a phase 1 interventional study registered as NCT05511844 by Orum Therapeutics USA, Inc., with 25 participants enrolled, started 2022-10-03. Conditions recorded: HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification and HER2 Gene Mutation. Interventions recorded: ORM-5029.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05511844
- Phase: 1
- Setting: Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
- Sponsor: Orum Therapeutics USA, Inc.
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT05511844: https://clinicaltrials.gov/study/NCT05511844

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [ORM-5029](https://onco.cc/drugs/orm-5029/)
- companies: [Orum Therapeutics](https://onco.cc/companies/orum-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05511844.json